Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(11):1849-1850; doi:10.1093/annonc/mdi357
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Letter to the Editor |
Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma
| The first 10% of the full text of this article appears below. |
Thalidomide is an effective treatment both in advanced multiple myeloma (MM) and as first-line therapy in combination with dexamethasone or other cytotoxic chemotherapy [1
, 2
].
Two cases [3
, 4
] of pulmonary hypertension in the absence of thromboembolic events have been described in patients with MM during thalidomide treatment [5
].
A 63-year-old woman was diagnosed in
1 Department of Department of Haematology, University of Florence, Azienda Ospedaliera Careggi, Florence; 2 Department of Oncology, General Hospital S.Giuseppe, Empoli, Florence; 3 Department of Medicine, General Hospital S.Giuseppe, Empoli, Florence, Italy
* E-mail: c.nozzoli@dac.unifi.it
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas Nonthromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study Ann. Onc., May 13, 2008; (2008) mdn287v1. [Abstract] [Full Text] [PDF] |
||||
